Key result
Compared with placebo, ranolazine reduced A1C levels and fasting serum glucose in patients with diabetes.
Why the study?
Does ranolazine improve HbA1c and fasting serum glucose in diabetic patients?
Meta-Analysis (n=4,461)
Does ranolazine improve HbA1c and fasting serum glucose in diabetic patients?
Ranolazine significantly improves glycemic control (A1C and fasting glucose) in diabetic patients without increasing the risk of hypoglycemia or MACE.
Answers are grounded in this paper and cite their sources.
Expands ranolazine's role to glycemic control in diabetes; reinforces pooled RCT evidence on metabolic effects.
BACKGROUND: Recent studies have discovered that the antiangina agent ranolazine exerts a glucometabolic effect. OBJECTIVE: This systematic review and meta-analysis aimed to further understand the efficacy and safety profile of ranolazine in patients with diabetes. METHODS: (A1C) and fasting serum glucose (FSG) levels. Safety end points included the incidence of hypoglycemia, persistent hyperglycemia, and major adverse cardiovascular events (MACE). Sensitive and subgroup analyses were also conducted. RESULTS: Seven RCTs with 4461 diabetic patients were selected. Compared with placebo, the use of ranolazine significantly reduced the levels of A1C (weighted mean difference [WMD] = -0.49%; 95% CI = -0.58 to -0.40; P < 0.00001) and FSG (WMD = -6.70 mg/dL; 95% CI = -11.87 to -1.52; P = 0.01). No significant differences were observed in the rates of hypoglycemia (relative risk [RR] = 1.17; 95% CI = 0.76 to 1.80; P = 0.47), persistent hyperglycemia (RR = 0.78; 95% CI = 0.47 to 1.31; P = 0.35), and MACE (RR = 0.65; 95% CI = 0.32 to 1.32; P = 0.23). CONCLUSION: Ranolazine exerts a positive effect on glucose control and is a well-tolerated agent for patients with diabetes.
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2017) conducted a meta-analysis in Diabetes (n=4,461). Ranolazine vs. Placebo was evaluated on A1C levels (WMD -0.49%, 95% CI -0.58 to -0.40, p=< 0.00001). Compared with placebo, ranolazine reduced A1C levels and fasting serum glucose in patients with diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: